AAPL340.86-2.08 (-0.61%) ▼|ABBV289.30+6.62 (+2.34%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|AAPL340.86-2.08 (-0.61%) ▼|ABBV289.30+6.62 (+2.34%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|
17.9 C
New York
Tuesday, October 20, 2026

Tag: treatment

newsFORsourcecompanycontentinformation1releasesmarket

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

KBP’s Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration

SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025

Transparency-Driven Supplement Aligns With Growing Demand for Natural, Purposeful Formulations Supporting Active Lifestyles 
Transparency-Driven Supplement Aligns With Growing Demand for Natural, Purposeful Formulations Supporting Active Lifestyles

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Gait analysis and pain measures show that subtly adjusting the angle of the foot during walking may...

Global Digital Health Market Poised for Robust Growth at a CAGR of ~18% by 2032 Amid Rising Demand for Remote Care| DelveInsight

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Birches Health, a leading clinical provider of Gambling Addiction care, expands statewide access to specialized Problem Gambling treatment across Nevada

Birches Health, a leading clinical provider of Gambling Addiction care, expands statewide access to specialized Problem Gambling treatment across Nevada

The York Water Company Reports 2nd Quarter and Six Months Earnings

YORK, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- The York Water Company's (NASDAQ:YORW) President, JT Hand, announced the Company's financial results for the second quarter and the first six months of 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers